Related Experiment Video
Updated: Jun 24, 2026
11:55
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
Costimulation blockade in rheumatic diseases: where we are?
Vincent Goëb1, Maya H Buch, Edward M Vital
1Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS7 4SA, UK.
Current Opinion in Rheumatology
|April 4, 2009
Summary
Abatacept, a T-cell costimulation modulator, effectively treats rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). It shows sustained benefits in reducing RA structural damage and has a favorable safety profile when used with DMARDs.
Area of Science:
- Immunology
- Rheumatology
Background:
- T-cell activation plays a crucial role in the pathogenesis of rheumatoid arthritis (RA).
- Abatacept (CTLA4-Ig) represents a novel therapeutic approach by selectively modulating T-cell costimulation.
Purpose of the Study:
- To elucidate the mechanisms of action of abatacept.
- To review the efficacy and safety data of abatacept in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
Main Methods:
- Review of clinical studies and trial data.
- Analysis of abatacept's impact on disease activity, quality of life, and structural damage progression.
- Assessment of safety profiles in combination therapies.
Main Results:
- Abatacept demonstrates significant clinical efficacy in RA patients unresponsive to conventional DMARDs and anti-TNF biologics.
- Evidence suggests abatacept is effective for JIA patients resistant to standard treatments.
- Long-term data indicates sustained inhibition of structural damage progression in RA.
Conclusions:
- Abatacept is an effective selective T-cell costimulation modulator for RA and JIA.
- Its favorable safety profile is noted when used with DMARDs, but caution is advised with other biologics.
- Sustained T-cell signaling blockade offers long-term benefits in preventing RA structural damage.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:29Neuromuscular Junction And Blockade
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...